Calidad de vida relacionada con la salud en pacientes oncológicos con enfermedad tromboembólica venosa aguda sintomáticadiseño del estudio QCA (quality of life in cancer), estudio de casos y controles

  1. L. Marín Barrera 1
  2. A.J. Muñoz Martín 2
  3. E. Ríos Herranz 3
  4. I. García-Escobar
  5. C. Beato
  6. C. Font
  7. E. Oncala Sibajas 4
  8. A. Revuelta Rodríguez 5
  9. M.C. Areses
  10. V. Rivas Jiménez
  11. M.A. Moreno Santos 6
  12. I. Gallego Gallego 2
  13. T. Elías Hernández 1
  14. M.I. Asensio Cruz 1
  15. G. García González 2
  16. R. Otero Candelera 1
  17. L. Jara Palomares 1
  18. A. Ballaz Quincoces
  1. 1 Unidad médico-quirúrgica de enfermedades respiratorias, Hospital Universitario Virgen del Rocío
  2. 2 Oncología médica, Hospital General Universitario Gregorio Marañón
  3. 3 Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de Valme
  4. 4 Servicio de urgencias, Hospital Virgen Macarena
  5. 5 Oncología médica, Hospital Universitario Central de Asturias
  6. 6 1Oncología médica, Hospital Universitario Puerto Real
Revista:
Revista española de patología torácica

ISSN: 1889-7347

Año de publicación: 2019

Volumen: 31

Número: 4

Páginas: 249-258

Tipo: Artículo

Otras publicaciones en: Revista española de patología torácica

Resumen

The association between cancer and venous thromboembolic disease (VTD) is well established. VTD presents a high rate of morbidity and mortality, with patients with cancer showing an increased risk of VTD that is up to 4 times greater than the general population. However, there is little scientific evidence on HRQoL (health-related quality of life) in cancer patients with VTD when this disease is likely to be an aggravating factor in perceived state of health among cancer patients. Our objective is to present the QCa study, which aims to evaluate the HRQoL of cancer patients with acute symptomatic VTD in comparison with cancer patients without VTD. The QCa study is a prospective, case-control national cohort study in patients with active cancer. We define “case” as a cancer patient with acute symptomatic VTD and “control” as a cancer patient without acute symptomatic VTD. Inclusion criteria for cases were: having active cancer at the time of inclusion, being over the age of 18, patients diagnosed with acute symptomatic deep vein thrombosis (DVT) in the lower extremities or pulmonary embolism (EP) that was objectively confirmed through imaging tests, and having signed the informed consent. For the controls: having active cancer, being over the age of 18, and having signed the informed consent. Given the scarce data published with regard to HRQoL in patients with VTD, we designed the QCa study to determine the impact VTD has on the quality of life of patients with cancer.